Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder, which affects 20 to 30 million individuals worldwide. Currently, no effective therapies to treat or cure this disease have been developed. In this review, we discuss the current research and understanding of the PSEN1 gene and its mutation which causes familial Alzheimer's disease (FAD).

 

Background Information – PSEN1 & Homologs Across Species

 

1. Human PSEN1 Gene

Gene location: Chromosome 14 (14q24.2)

Full length: spans 87 kb and includes 14 exons 

Values of amino acid: 467AA

Conservation: Nematodes, fruit flies, and all vertebrates

Cleavage product: Notch receptor, APP

Cell location: membrane protein

Protein molecular weight: ~53kd

Gene family: PSEN2

Aliases: PS1, Presenilin 1, PS-1, Presenilin-1, S182, Protein S182, AD3, Alzheimer Disease 3, FAD

Related diseases: Alzheimer's disease (AD), Pick's disease, familial dilated cardiomyopathy

 

2. Mouse Psen1 Gene

Gene location: Chromosome 12 (12D1; 12 38.84cM)

Full length: spans 47kb and includes 12 exons 

Knockout (KO): Nerve regeneration is impaired, and loss of neurons

Overexpression: No significant phenotype

Common models: 5×FAD, 3×Tg, APP/PS1

 

3. Rat Psen1 Gene

Gene location: Chromosome 11 (11q11)

Full length: Spans 217 kb and includes 18 exons 

Knockout (KO): No validation data

Overexpression: No information

Common models: APP21, APPKI, APPPS1

 

 

Overview of PSEN1 Gene Research

 

PSEN1 is gene associated with familial Alzheimer's disease that encodes the Presenilin 1 protein. Some mutations of this gene can cause the increased production of the toxic, longer form of amyloid-beta (Aβ) fragments to be initiated. The protein encoded by this gene is the active part of gamma- (γ-) secretase, a multi-subunit protease complex is involved in the cleavage of Notch receptors, with PSEN1 participating in the release of synaptic transmitters in hippocampal vertebral neuritis. This suggests that presenilin 1 plays a critical role in the Notch signaling pathway.

 

Currently, there are 318 mutations of PSEN1 that have been identified, but more are added every year. Of these mutations, around 300 are linked to Alzheimer's disease, and some are related to other neurological diseases such as Pick's disease, frontotemporal dementia, Amyotrophic lateral sclerosis (ALS), and more.

Figure 1. The Distribution of PSEN1 Mutation

(Source: https://www.alzforum.org/mutations/psen-1)

The Distribution of PSEN1 Mutation | Cyagen 

(Left) N-terminal sequence; (Right) C-terminal sequence; Red circle - pathogenic mutation; Yellow - protective mutation; Blue - unknown phenotype of the mutation; Arrows indicate possible deletion or insertion mutations. The proteins encoded by different exons are separated by lines.

                                                                               

The function of PS1 (Presenilin 1) can be divided into γ-secretase-dependent and γ-secretase-independent regions. Current research shows that both membrane receptors amyloid precursor protein (APP) and Notch are cleaved by the γ-secretase. PSEN1 alone can stabilize β-Catenin in the Wnt signaling pathway, serving as a negative regulator in Wnt signaling. Calcium signaling in related pathways is regulated by the combination of original calcium ion (Ca2+) channels or as Ca2+ channels independently functioning in the endoplasmic reticulum (ER). The lysosome-associated functions during autophagy are all regulated by PSEN1, and the phenotype also regulates the plasticity of synapses.

Figure 2. Signaling Pathway of PSEN1[1]

 Signaling Pathway of PSEN1[1] | Cyagen

 

 

PSEN1 Expression in Human Tissues

 

PSEN1 is highly expressed in brain, rectum, testes, thymus, and urinary system. However, the expression abundance is low in fat and bone tissues, as well as in the heart, ovaries, spleen, and stomach.

Figure 3. PSEN1 Expression (relative expression values)

 PSEN1 Expression (relative expression values) | Cyagen 

Additional Resources

 

As AD research has progressed, there has been a large movement towards the use of rat models, mainly due to drug development efforts centered on the amyloid hypothesis failing in clinical trials (wherein mouse models were used). Our experts have put together an article describing the advantages that rats may provide in researching AD and related neurodegenerative disorders. View the full text:

Applications of Rat Models in Alzheimer's Disease Discovery Research.

 

References:

 

  1. Zhang S, Zhang M, Cai F, Song W. Biological function of Presenilin and its role in AD pathogenesis. Transl Neurodegener. 2013;2(1):15. DOI:10.1186/2047-9158-2-15
  2. Walter J. Twenty Years of Presenilins--Important Proteins in Health and Disease. Mol Med. 2015 Oct;21 Suppl 1(Suppl1):S41-S48. DOI:10.2119/molmed.2015.00163
  3. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997 Apr;20(4):154-9. DOI: 10.1016/s0166-2236(96)01030-2. PMID: 9106355.

 

 

About Cyagen

Cyagen is a 400-employee company headquartered in Santa Clara, California, with additional locations in Japan and China, and production facilities in China. In under 15 years since its founding, Cyagen has become a leading provider of custom mouse and rat models – delivering over 50,400 models to researchers worldwide and receiving over 3,600 peer-reviewed citations. Cyagen provides researchers from around the world with transgenic, knockout, knockin, conditional knockout mouse and rat models and also offers a comprehensive series of stem cell products for research use, including cell lines, media, and differentiation kits.